NYXH

Nyxoah

5.24 USD
-0.31
5.59%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
5.24
0.00
0%
1 day
-5.59%
5 days
-12.67%
1 month
-21.67%
3 months
-30.69%
6 months
-46.15%
Year to date
-42.04%
1 year
-33.16%
5 years
-82.6%
10 years
-82.6%
 

About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Employees: 184

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

12% more funds holding

Funds holding: 26 [Q1] → 29 (+3) [Q2]

5.62% less ownership

Funds ownership: 15.98% [Q1] → 10.37% (-5.62%) [Q2]

31% less capital invested

Capital invested by funds: $41.8M [Q1] → $29M (-$12.8M) [Q2]

Financial journalist opinion

Based on 8 articles about NYXH published over the past 30 days

Neutral
Seeking Alpha
4 days ago
Nyxoah SA (NYXH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Nyxoah SA (NASDAQ:NYXH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Olivier Taelman - CEO & Executive Director Presentation Unknown Analyst Excellent. Thank you, everyone, for joining us.
Nyxoah SA (NYXH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral
Benzinga
7 days ago
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Neutral
GlobeNewsWire
8 days ago
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 5, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On September 4, 2025, Nyxoah received a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd following a passive crossing of a threshold.
Publication relating to transparency notifications
Neutral
GlobeNewsWire
11 days ago
Nyxoah Announces Upcoming Investor Events
Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September: 2025 Wells Fargo Healthcare Conference September 3rd – Boston, MA Cantor Global Healthcare Conference 2025 September 4th – New York, NYFireside Chat: 11:30-12:00 pm ETWebcast: Cantor Fireside Chat Webcast Morgan Stanley 23 rd Annual Global Healthcare Conference September 9th – New York, NY Presentation Time: 5:35-6:10 pm ETWebcast: : Morgan Stanley Fireside Chat Webcast Baird's 2025 Global Healthcare Conference September 10th – New York, NY A live webcast of the events can be accessed by visiting Nyxoah's Investor Relations website and will be available for replay following the events. The Company will also be available for 1x1 meetings with institutional investors attending the events.
Nyxoah Announces Upcoming Investor Events
Positive
Seeking Alpha
25 days ago
Nyxoah: High-Risk High-Reward Medtech To Own
Nyxoah's Genio system received FDA approval, unlocking access to the US market and validating its innovative, patient-friendly OSA treatment. Recent earnings show strong revenue growth but continued losses as Nyxoah invests heavily in US commercialization and expansion efforts. Key risks include rising debt, dilution, ongoing patent litigation, and high competition, but GLP-1 drugs pose less threat than initially feared.
Nyxoah: High-Risk High-Reward Medtech To Own
Neutral
Seeking Alpha
26 days ago
Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript
Nyxoah SA (NASDAQ:NYXH ) Q2 2025 Earnings Conference Call August 18, 2025 4:30 PM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO & Executive Director Pearson Dennis - Corporate Participant Conference Call Participants David Kenneth Rescott - Robert W. Baird & Co. Incorporated, Research Division Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division Junwoo Park - Cantor Fitzgerald & Co., Research Division Kyle Edward Winborne - Piper Sandler & Co., Research Division Michael K.
Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
26 days ago
Nyxoah Reports Second Quarter Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating Results FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in the U.S. Kicked off the U.S. commercial launch of the Genio system DREAM pivotal study data published in the Journal of Clinical Sleep Medicine Revenue for the second quarter of 2025 was €1.3 million, compared to €0.8 million in the second quarter of 2024, representing 74% year over year growth Cash, cash equivalents and financial assets were €43.0 million at June 30, 2025, compared to €63.0 million at the end of March 31, 2025.
Nyxoah Reports Second Quarter Financial and Operating Results
Positive
Zacks Investment Research
1 month ago
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
Neutral
GlobeNewsWire
1 month ago
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.   Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Neutral
GlobeNewsWire
1 month ago
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA.
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
Charts implemented using Lightweight Charts™